Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Relative risk of breast cancer and 95% confidence intervals according to genotype of ATM haplotype tagging single nucleotide polymorphisms (SNPs) in the Nurses' Health Study (1989–2000)

From: Common ataxia telangiectasia mutated haplotypes and risk of breast cancer: a nested case–control study

SNP Genotype Casesa Controlsa Relative riskb Relative riskc
SNP1 T/T 450 (35.3) 556 (33.9) 1.00 (Reference) 1.00 (Reference)
  T/A 575 (45.1) 762 (46.4) 0.94 (0.79–1.11) 0.94 (0.79–1.12)
  A/A 249 (19.5) 324 (19.7) 0.95 (0.77–1.17) 0.94 (0.75–1.17)
SNP2 A/A 1158 (90.5) 1495 (90.5) 1.00 (Reference) 1.00 (Reference)
  A/C 118 (9.2) 154 (9.3) 1.00 (0.77–1.30) 1.02 (0.78–1.34)
  C/C 4 (0.3) 3 (0.2) 1.64 (0.36–7.45) 2.07 (0.42–10.26)
SNP3 G/G 455 (35.8) 553 (34.3) 1.00 (Reference) 1.00 (Reference)
  G/A 570 (44.9) 755 (46.8) 0.99 (0.83–1.17) 0.99 (0.83–1.18)
  A/A 245 (19.3) 306 (19.0) 1.03 (0.83–1.28) 1.03 (0.82–1.29)
SNP4 A/A 164 (12.7) 189 (11.0) 1.00 (Reference) 1.00 (Reference)
  A/C 565 (43.9) 759 (44.0) 0.88 (0.69–1.12) 0.87 (0.68–1.12)
  C/C 559 (43.4) 778 (45.1) 0.86 (0.67–1.09) 0.85 (0.66–1.09)
SNP5 C/C 970 (75.7) 1207 (73.1) 1.00 (Reference) 1.00 (Reference)
  C/A 292 (22.8) 417 (25.2) 0.87 (0.73–1.04) 0.86 (0.72–1.04)
  A/A 20 (1.6) 28 (1.7) 0.81 (0.45–1.47) 0.81 (0.44–1.50)
  1. a Data presented as n (%). Numbers may not add to totals due to missing genotype data. b Relative risks are crude odds ratios from conditional logistic regression models (95% confidence interval). c Relative risks (95% confidence interval) are from conditional logistic regression models adjusted for age at menarche (< 12 years, 12 years, 13 years, > 13 years), age at menopause (≤ 45 years, 46–50 years, 51–60 years), first-degree family history of breast cancer (yes/no), personal history of benign breast disease (yes/no), weight gain since age 18 (< 5 kg, ≥ 5 to < 20 kg, ≥ 20 kg), body mass index at age 18 (continuous), age at first birth/parity (nulliparous, one to four children/age at first birth ≤ 24 years, one to four children/age at first birth > 24 years, five or more children/age at first birth ≤ 24 years, five or more children/age at first birth > 24 years), and duration of postmenopausal hormone use (premenopausal, never, past user < 5 years duration, past user ≥ 5 years duration, current user < 5 years duration, current user ≥ 5 years duration).